Legal & General Group Plc bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,237 shares of the company's stock, valued at approximately $4,155,000.
Other institutional investors also recently made changes to their positions in the company. Merck & Co. Inc. acquired a new stake in Kymera Therapeutics in the 2nd quarter valued at approximately $88,544,161. Deutsche Bank AG bought a new position in shares of Kymera Therapeutics during the 2nd quarter valued at about $12,161,000. Eagle Health Investments LP acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth approximately $19,052,000. BlackRock Inc. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth approximately $635,067,000. Finally, Maven Securities LTD acquired a new stake in Kymera Therapeutics during the fourth quarter valued at approximately $1,167,000.
Analyst Ratings Changes
Several research analysts have issued reports on KYMR shares. Canaccord Genuity Group lifted their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a "buy" rating in a research report on Friday, June 26th. Citigroup restated a "buy" rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada cut shares of Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and lifted their price objective for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Brookline Capital Markets reiterated a "buy" rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Finally, Bank of America boosted their target price on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $128.70.
Read Our Latest Analysis on KYMR
Insider Buying and Selling
In other news, CFO Bruce Jacobs sold 77,109 shares of the business's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares in the company, valued at $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Noah Goodman sold 3,389 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total value of $387,328.81. Following the transaction, the insider directly owned 47,179 shares in the company, valued at $5,392,087.91. This trade represents a 6.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,594,000 shares of company stock worth $386,928,106. 15.98% of the stock is currently owned by company insiders.
Kymera Therapeutics Stock Performance
Shares of KYMR stock opened at $117.39 on Friday. Kymera Therapeutics, Inc. has a 52 week low of $42.22 and a 52 week high of $130.05. The stock's fifty day moving average is $114.16 and its 200-day moving average is $94.90. The stock has a market capitalization of $9.76 billion, a PE ratio of -36.23 and a beta of 1.96.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter last year, the business posted ($0.95) earnings per share. Kymera Therapeutics's revenue for the quarter was up 465.2% compared to the same quarter last year. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current fiscal year.
About Kymera Therapeutics
(
Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
